Methods of treating Parkinson's disease

Abstract

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

What is claimed is: 
     
       1. A method of delivering dopamine to a Parkinson's disease patient in a pharmacokinetically-consistent manner comprising, continuously subcutaneously administering an aqueous pharmaceutical formulation to the patient, the formulation comprising:
 (a) at least about 5 mg/mL of a compound comprising levodopa, 
 (b) carbidopa, or a pharmaceutically acceptable salt thereof, and 
 (c) an aqueous carrier, 
 
       wherein the method is sufficient to achieve a steady state levodopa plasma level of about 1000 ng/ml to about 5000 ng/ml in the patient for at least 8 hours without co-administration of a catechol-0-methyl transferase inhibitor. 
     
     
       2. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient for at least 16 hours. 
     
     
       3. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient for at least 24 hours. 
     
     
       4. The method of  claim 1 , wherein the steady state levodopa plasma level in the patient is achieved without an oral medication for Parkinson's Disease. 
     
     
       5. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient of about 1000 ng/ml +/− about 10%. 
     
     
       6. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient of about 2000 ng/ml +/− about 10%. 
     
     
       7. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient of about 3000 ng/ml +/− about 10%. 
     
     
       8. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient from about 1500 ng/ml to about 5000 ng/ml. 
     
     
       9. The method of  claim 8 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient for at least 16 hours. 
     
     
       10. The method of  claim 8 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient for at least 24 hours. 
     
     
       11. The method of  claim 1 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient from about 2000 ng/ml to about 4000 ng/ml. 
     
     
       12. The method of  claim 11 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient for at least 16 hours. 
     
     
       13. The method of  claim 11 , wherein the method is sufficient to achieve a steady state levodopa plasma level in the patient for at least 24 hours. 
     
     
       14. The method of  claim 1 , wherein the formulation comprises at least about 10 mg/mL of the compound comprising levodopa. 
     
     
       15. The method of  claim 1 , wherein the formulation comprises at least about 20 mg/mL of the compound comprising levodopa. 
     
     
       16. The method of  claim 1 , wherein the formulation comprises at least about 30 mg/mL of the compound comprising levodopa. 
     
     
       17. The method of  claim 1 , wherein the formulation comprises at least about 50 mg/mL of the compound comprising levodopa.